Table 1.
Baseline demographic and clinical characteristics of 23 mCRC patients.
| Characteristics | Patients N (%) |
|---|---|
| Age (year) | |
| Median age (range) | 50 (33–73) |
| ≤60 | 17 (73.9) |
| >60 | 6 (26.1) |
| Gender | |
| Male | 16 (69.6) |
| Female | 7 (30.4) |
| EGOG performance status | |
| 0 | 6 (26.1) |
| 1 | 14 (60.9) |
| 2 | 3 (13.0) |
| Primary tumor location | |
| Colon | 13 (56.5) |
| Right-side | 6 (26.1) |
| Left-side | 7 (30.4) |
| Rectum | 10 (43.5) |
| Type of metastasis | |
| Synchronous | 12 (52.2) |
| Metachronous | 11 (47.8) |
| With liver metastasis | 13 (56.5) |
| Without liver metastasis | 10 (43.5) |
| Previous treatment agents | |
| 5-Fluorouracil | 23 (100.0) |
| Oxaliplatin | 22 (95.7) |
| Irinotecan | 23 (100.0) |
| Bevacizumab | 19 (82.6) |
| Cetuximab | 9 (39.1) |
| Regorafenib | 9 (39.1) |
| Previous lines of chemotherapy | |
| Two lines | 8 (34.8) |
| Three lines | 6 (26.1) |
| Four or more lines | 9 (39.1) |
| Gene mutation status | |
| RAS/BRAF wild-type | 10 (43.5) |
| RAS mutant | 12 (52.2) |
| BRAF mutant | 1 (4.3) |
| MMR or MSI status | |
| pMMR or MSS | 23 (100.0) |
| dMMR or MSI-H | 0 (0) |
| PD-L1 expression level | |
| PD-L1 CPS unknown | 18 (78.3) |
| PD-L1 CPS<1 | 4 (17.4) |
| PD-L1 CPS≥1 | 1 (4.3) |
CPS, combine positive score; ECOG, Eastern Cooperative Oncology Group;
PD-L1, programmed death-ligand 1.